Trial results for atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC) were posted on ClinicalTrials.gov on 2025-12-12. The study investigated organ-specific responses, reporting percentages of lesions with response ranging from 19.0% to 40.5%.
Background
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths globally. For patients diagnosed at an advanced stage, systemic therapy, including immune-checkpoint inhibitors (ICI), is a primary treatment approach. Previous studies have indicated that ICI monotherapy has not consistently improved overall survival in advanced HCC in phase III trials, and responses can vary significantly across different organs, with intrahepatic HCC often showing the least responsiveness.
Trial design
This completed trial (NCT04862949) enrolled 131 participants with Advanced Hepatocellular Carcinoma. The study investigated the organ-specific responses to the combination of atezolizumab plus bevacizumab.
Key results
The trial measured the percentage of lesions with organ-specific response in patients treated with atezolizumab plus bevacizumab. The reported percentages were:
- 29.8% of lesions
- 28.3% of lesions
- 40.5% of lesions
- 29.1% of lesions
- 19.0% of lesions
What this means
The results from this trial highlight the variability in organ-specific responses to atezolizumab plus bevacizumab in patients with Advanced Hepatocellular Carcinoma. The observed range of lesion responses, from 19.0% to 40.5%, underscores the importance of understanding how different tumor locations may react to treatment. This information could be valuable for clinicians when considering treatment strategies and predicting outcomes based on the primary sites of disease.
Source
The information regarding these trial results was obtained from ClinicalTrials.gov, a public database of clinical studies. The results for study NCT04862949, titled "Organ-specific Responses to Atezolizumab Plus Bevacizumab in Advanced HCC," were posted on 2025-12-12 on clinicaltrials.gov.